Loren Data's SAM Daily™

SAMDAILY.US - ISSUE OF JANUARY 28, 2026 SAM #8829
SOLICITATION NOTICE

65 -- Intent to Sole Source Good Manufacturing Practices (GMP) Influenza A Primer Kits

Notice Date

1/26/2026 12:57:48 PM
 

Notice Type

Presolicitation
 

NAICS

325413 — In-Vitro Diagnostic Substance Manufacturing
 

Contracting Office

CDC OFFICE OF ACQUISITION SERVICES ATLANTA GA 30333 USA
 

ZIP Code

30333
 

Solicitation Number

75D301-26-Q-78825
 

Response Due

2/9/2026 2:00:00 PM
 

Archive Date

02/24/2026
 

Point of Contact

Dawnnia Daley, Phone: 4044986079, Liubov Kriel, Phone: 7704882856
 

E-Mail Address

xwf5@cdc.gov, vyh1@cdc.gov
(xwf5@cdc.gov, vyh1@cdc.gov)
 

Description

The Center for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases Influenza Division (NCIRD/ID), intends to award a sole source, firm fixed price purchase order in accordance with FAR 13.101(b), soliciting from a single source, to Biosearch Technologies Inc., Address: 2199 S McDowell Boulevard EXT, Petaluma, CA, 94954, for Good Manufacturing Practices (GMP) Influenza A Primer Kits. The purpose of this acquisition is to establish a contract to meet the current requirements for specifically designed oligonucleotide reagents of GMP quality level as defined under 21 CFR 820. The Contractor will manufacture oligonucleotide primers using their validated process. The NAICS code for this procurement is 325413, In-Virtro Diagnostic Substance Manufacturing. The Influenza Division of the Centers for Disease Control and Prevention (CDC) monitors and investigates influenza viruses that are the causative agents of influenza disease in humans. Genomic surveillance of influenza can be supported by Research Use Only (RUO) tests that amplify influenza viruses in clinical specimens and virus culture, and use this amplified material for genomic sequencing. The Influenza Division has created a method of amplifying all eight gene segments of Influenza A viruses in a one-step multi-segment reverse transcription polymerase chain reaction (M-RTPCR) reaction. As a result of this notice, no competitive solicitation will be posted on SAM.gov. The government will issue and negotiate only one solicitation to Biosearch Technologies Inc. However, firms that believe they can meet this requirement are encouraged to identify themselves and give written notice by providing a capability statement to the contract specialist, Dawnnia Daley, at xwf5@cdc.gov by February 9, 2026, at 5:00 p.m. ET. The contract specialist will not respond to verbal requests. All requests must be in writing. A determination by the government not to take this proposed action will be based on responses to this notice and is solely within the discretion of the contracting officer. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Inquiries shall reference the solicitation number, 75D301-26-Q-78825, on the subject line and be sent to Dawnnia Daley by email at xwf5@cdc.gov.
 

Web Link

SAM.gov Permalink
(https://sam.gov/workspace/contract/opp/83cb74ad165f42f9aab8988027a5ed74/view)
 

Place of Performance

Address: Petaluma, CA 94954, USA

Zip Code: 94954

Country: USA
 

Record

SN07697050-F 20260128/260126230038 (samdaily.us)
 

Source

SAM.gov Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |